AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02029339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous topical triple-tube irrigation and suction
Description: The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China).
Study NCT02029339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
Study NCT02417844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin (Astellas)
Study NCT02417844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin HCL
Study NCT00988325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu
Description: oral repeating dose
Study NCT00728078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: thalidomide 50mg tid for 6 months
Study NCT01785095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH (Follicle Stimulating Hormone)
Study NCT03124238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage therapy localized to the back of the individuals for a duration of 30 minutes
Study NCT03686488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS 102 35 mg will be administered orally twice daily every 2 weeks.
Study NCT03686488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
Description: Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
Study NCT04096365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcostal Temporary Extracardiac Pacing Lead
Description: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
Study NCT02401529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Description: 0.15 mg/kg
Study NCT02401529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Description: 0.25mg/kg/day for 7 days then tapering for next 7 days
Study NCT02401529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: acetaminophen 15 mg/kg/dose every 6 hours
Study NCT02401529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: acetaminophen 15 mg/kg/dose every 6 hours
Study NCT02401529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV saline
Description: IV saline
Study NCT02968940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenously (IV) every 2 weeks
Study NCT01871857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline and epinephrine
Study NCT01871857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline and epinephrine
Study NCT02670343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Testosterone Undecanoate
Description: Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
Study NCT02933580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
Study NCT02968940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HFRT)
Description: Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
Study NCT02938728 — intervention group
Intervention type: OTHER
Intervention: Biopsies
Study NCT01220674 — intervention group
Intervention type: OTHER
Intervention: cognitive testing
Description: computer-based cognitive assessment
Study NCT03644134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of physiological stress and sleep pattern
Description: The personalized intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
Study NCT04581681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)
Description: The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer \& Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform.
Study NCT04581681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment (waitlist control)
Description: Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
Study NCT03421990 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: general anesthesia and regional anesthesia techniques are used
Study NCT04921995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 1. Chemotherapy (including but not limited to following):~   GP regimen: gemcitabine 1000mg/m2 d1, d8 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4-6 cycles; GX regimen: gemcitabine 800mg/m2 d1 + capecitabine 750 mg/m2 d1-14, every 3 weeks for 4-6 cycles.~   Capecitabine: 750 mg/m2 d1-14, every 3 weeks until unacceptable toxicities or patient's withdraw.~2. anti-PD-1 antibody: Tislelizumab concurrently with chemotherapy: 200mg, every 3 weeks for 12 weeks. Tislelizumab in maintenance period: 200mg every 3 weeks or 400mg every 6 weeks, until one year or disease progression, or in the case of intolerable toxicities.
Study NCT02933580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets on Day 1.
Study NCT01542671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: * Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~* Monthly Motivational phone calls with Lifestyle Counselor for the first year~* 4 informational DVDs over the two year period~* Feedback on submitted food and exercise journals
Study NCT02816684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pegasys-VR
Description: Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
Study NCT02816684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Effectiveness Therapy for Children
Description: Group social skills training, peer generalization sessions, individual exposure therapy
Study NCT01542671 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: * Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* 5 informational NIDDK mailings over the two year period
Study NCT04040868 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: the TiRobot system
Description: The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
Study NCT04040868 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Freehand
Description: conventional fluoroscopy-assisted
Study NCT01565837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
Study NCT01565837 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiosurgery (SART)
Description: Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
Study NCT02525315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation: rTMS
Description: 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
Study NCT02369562 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of the failure rate of dental implants
Description: Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
Study NCT04105829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bond-a braid
Description: Stainless steel lingual retainer application
Study NCT04105829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EverStick-Ortho
Description: Fiber reinforced lingual retainer
Study NCT04105829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ribbond
Description: Fiber reinforced lingual retainer
Study NCT02763761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab + Prednisone
Description: Prednisone dose will be decreased every 3 days for 18 days
Study NCT02763761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone + Prednisone
Description: Prednisone dose will be decreased every 4 days for 40 days
Study NCT06087003 — intervention group
Intervention type: DRUG
Intervention: Basiliximab Injection
Description: As an induction treatment for kidney transplantation
Study NCT06087003 — intervention group
Intervention type: DRUG
Intervention: rabbit ATG
Description: As an induction treatment for kidney transplantation
Study NCT06353230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection 5% phenol in almond oil
Description: Group A were given 5% phenol in almond oil
Study NCT06353230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 5% phenol in almond oil
Description: Group A were given 5% phenol in almond oil
Study NCT06353230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection 15% hypertonic saline
Description: Group B were given hypertonic saline
Study NCT06353230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 15% hypertonic saline
Description: Group B were given hypertonic saline
Study NCT06353230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection 50% dextrose water
Description: group C were given 50% dextrose water
Study NCT06353230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 50% dextrose water
Description: group C were given 50% dextrose water
Study NCT01452009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.004% (New Formulation)
Description: Travoprost Ophthalmic Solution, 0.004% given one drop once daily
Study NCT01452009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAVATAN®
Description: TRAVATAN® administered one drop once daily
Study NCT03387150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
Study NCT03387150 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9%; administered by IM injection
Study NCT00403403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
Study NCT00403403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
Study NCT00403403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
Study NCT00403403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
Study NCT02708758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy
Description: individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
Study NCT05079555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic rehab
Description: Patients using the robotic platform SWalker
Study NCT01292668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-5-aminolevulinate hydrochloride cream
Description: Applied topically
Study NCT01292668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo light-emitting diode photodynamic therapy
Study NCT01292668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Undergo laser light photodynamic therapy
Study NCT02086838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theragran Hematinic
Study NCT02086838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight iron dextran
Study NCT01390051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innohep (Tinzaparin)
Description: Dose: 4,500 IU daily in half of the study populationrandomised to treatment
Study NCT01390051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinzaparin
Description: Dose 4,500 IE daily
Study NCT02156219 — intervention group
Intervention type: OTHER
Intervention: Separation of women and men in the metro of Mexico City
Description: The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~1. Control: Surveillance that men do not use cars corresponding to women.~2. Dosage: Regulation of entry women.~3. Assignment: Of the women, to the part of the platform where the first wagons stop.
Study NCT02724072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoraflex™ Hybrid Device
Description: Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
Study NCT03985098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention arm
Description: The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
Study NCT02110927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous microcurrent
Description: Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
Study NCT02110927 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: 50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
Study NCT02110927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
Study NCT02060253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Given IV
Study NCT02060253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT02060253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT04271488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasurgratinib
Description: Tasurgratinib oral capsule.
Study NCT00096005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00096005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00096005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT06692049 — intervention group
Intervention type: PROCEDURE
Intervention: Gonadectomy
Description: Gonadal tissue being removed for risk of malignancy may be cryopreserved for fertility preservation
Study NCT03654248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get Organized group intervention
Description: Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
Study NCT03951727 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular treatment for PAD
Description: Long femoropopliteal stenting with SuperA devices
Study NCT03654248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individual Occupational Therapy
Description: Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
Study NCT02060253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Given IV